The Prevalence and Incidence of Suicidal Thoughts and Behavior in a Smartphone-Delivered Treatment Trial for Body Dysmorphic Disorder: Cohort Study
JMIR Mental Health · 2025
DOI: 10.2196/63605 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Mental Health, 2025. Verfasst von Adam C Jaroszewski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiarty, Massachusetts General Hospital, Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA, 02114,…. Hauptthemen laut MEDLINE: Suicidal Ideation, Cognitive Behavioral Therapy, Smartphone, Body Dysmorphic Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Abstract (Originalsprache)
Background
People with past suicidal thoughts and behavior (STB) are often excluded from digital mental health intervention (DMHI) treatment trials. This may perpetuate barriers to care and reduce treatment generalizability, especially in populations with elevated rates of STB, such as body dysmorphic disorder (BDD). We conducted a cohort study of randomized controlled trial (RCT) participants (N=80) who received a smartphone-based cognitive behavioral therapy (CBT) treatment for BDD that allowed for most forms of past STB, except for past-month active suicidal ideation.
Objective
This study had two objectives: (1) to characterize the sample’s lifetime prevalence of STB and (2) to estimate and predict STB incidence during the trial.
Methods
We completed secondary analyses on data from an RCT of smartphone-delivered CBT for BDD. The primary outcomes consisted of STB severity and suicide attempt assessed at baseline with the Columbia-Suicide Severity Rating Scale (C-SSRS) and weekly during the trial via one item from the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR item #12; 1043 observations). We computed descriptive statistics (n, %) and ran a series of bi- and multivariate linear regressions predicting STB incidence during the 3-month trial.
Results
At baseline, 40% of participants reported a lifetime history of active suicidal thoughts and 10% reported lifetime suicide attempts. During the 3-month trial, 42.5% reporting thinking about death or suicide via weekly assessment. No participants reported frequent or acute suicidal thoughts, plans, or attempts. Lifetime suicide attempt (odds ratio 11, 95% CI 2.14‐59.14; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiarty, Massachusetts General Hospital, Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, United States, 1 617-724-6300.
- Department of Psychology, Ferkauf Graduate School of Psychology, Yeshiva University, New York, NY, United States.
ORCID-Profile: Adam C Jaroszewski, Natasha Bailen, Simay I Ipek, Jennifer L Greenberg, Susanne S Hoeppner, Hilary Weingarden, Ivar Snorrason, Sabine Wilhelm
Förderung
- NIMH NIH HHS
Zitieren
APA
Jaroszewski, A. C., Bailen, N., Ipek, S. I., Greenberg, J. L., Hoeppner, S. S., Weingarden, H., Snorrason, I., & Wilhelm, S. (2025). The Prevalence and Incidence of Suicidal Thoughts and Behavior in a Smartphone-Delivered Treatment Trial for Body Dysmorphic Disorder: Cohort Study. JMIR Mental Health. https://doi.org/10.2196/63605
Vancouver
Jaroszewski AC, Bailen N, Ipek SI, Greenberg JL, Hoeppner SS, Weingarden H, et al. The Prevalence and Incidence of Suicidal Thoughts and Behavior in a Smartphone-Delivered Treatment Trial for Body Dysmorphic Disorder: Cohort Study. JMIR Mental Health. 2025. doi:10.2196/63605
BibTeX
@article{Jaroszewski2025,
author = {Jaroszewski, Adam C and Bailen, Natasha and Ipek, Simay I and Greenberg, Jennifer L and Hoeppner, Susanne S and Weingarden, Hilary and Snorrason, Ivar and Wilhelm, Sabine},
title = {The Prevalence and Incidence of Suicidal Thoughts and Behavior in a Smartphone-Delivered Treatment Trial for Body Dysmorphic Disorder: Cohort Study},
journal = {JMIR Mental Health},
year = {2025},
doi = {10.2196/63605}
}
EUVIMED